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Abstract
A new Mozambican guideline for management of fever in HIV-infected adults requires malaria 
testing and systematic consideration of specific alternative diagnoses (eg, tuberculosis and 
bacterial infections) in addition to malaria. We conducted a prospective observational study of the 
guideline’s performance. Of 258 HIV-infected subjects with axillary temperature ≥37.5° C or 
history of fever, 76.0% improved, 13.6% died or were hospitalized, and 10.5% were lost to follow-
up. In multivariate analyses, factors associated with adverse outcomes were bacterial blood stream 
infection, syndromically diagnosed tuberculosis, lower CD4+ T-lymphocyte count, no 
antiretroviral therapy, lower body mass index, lower hemoglobin, and nonprescription of 
antibiotics.
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BACKGROUND
Fever is common in HIV-infected adults in sub-Saharan Africa; its observed incidence was 
602.5/1000 person-years in one Kenyan cohort.1 The differential diagnosis of fever is 
broader in the HIV-infected adults and includes bacterial, mycobacterial, viral, parasitic, and 
fungal infections, adverse drug reactions, and malignancy.2–4 Health workers in resource-
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limited areas must often address this complex differential diagnosis with strictly syndromic 
guidelines.5 One such guideline, from the Integrated Management of Adolescent and Adult 
Illness strategy, recommends presumptive antimalarials for all with fever or history of fever 
in malaria-endemic regions, with consideration of antibiotics, glucose, and tuberculosis (TB) 
and HIV evaluation only under certain circumstances.6
Mozambique, a resource-limited country,7 adopted the acute care guideline of Integrated 
Management of Adolescent and Adult Illness for nonphysician clinicians managing fever in 
adults and adolescents. However, the guideline conflicted with the Mozambican Ministry of 
Health (MISAU) requirements for malaria testing before antimalarial treatment,8 and 
MISAU became concerned about underdiagnosis of common HIV-associated causes of 
fever. MISAU subsequently revised the guideline for use in HIV/AIDS care. The new 
version required a more comprehensive medical history (including TB screening questions) 
and physical examination, malaria testing, and broader consideration of antibiotics. 
However, because causes of fever are rarely diagnosed etiologically at under-capacitated 
Mozambican peripheral health units, the new guideline (disseminated in 2009) was based 
largely on syndromic assessments.
We conducted a study (NCT 01681914, www.clinicaltrials.gov) to describe the new fever 
guideline’s performance under Mozambican field conditions. The primary objectives were to 
measure (1) the proportion of febrile, ambulatory, HIV-infected adult patients who could be 
assigned an etiologic or syndromic diagnosis through application of the new guideline and 
(2) the proportion whose fevers improved with guideline-determined treatment.
METHODS
This prospective observational study was conducted in 3 health centers in Zambézia 
Province, Mozambique; its methods have been previously described.9 Briefly, ambulatory 
HIV-infected adults ≥18 years old with axillary temperature ≥37.5° C or history of fever 
(preceding 24 h) were eligible. Patients were ineligible if rapid preliminary evaluation 
detected guideline-determined danger signs or if unable to communicate in Portuguese or 
Echuabo (a local language). Random selection was not logistically feasible.
At enrollment, clinical evaluation included rapid assessment for prespecified danger signs, 
medical chart review, standardized history (including TB screening questions), and physical 
examination. Laboratory evaluation (previously described)9 included rapid antigen testing 
for Plasmodium falciparum malaria, rapid hemoglobin testing, and 1 set of bacterial blood 
cultures. Blood cultures were ordinarily unavailable in Zambézia Province and were strictly 
a study procedure. HIV testing, CD4+ T-lymphocyte (CD4) count, sputum microscopy for 
TB, complete blood counts, and certain blood chemistries could be requested at clinician 
discretion and were available through the local or provincial hospital laboratories.
Study clinicians (Mozambican nonphysician clinicians) assigned etiologic and/or syndromic 
diagnoses for causes of fever and developed treatment plans. If not hospitalized, subjects 
were asked to return in 7 days or sooner if there were complications. At follow-up, subjects 
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were discharged if fever had resolved. If unimproved, subjects were scheduled for further 
visits until reaching a study end point.
Predefined end points (previously described)9 were hospitalization, death, improvement of 
fever (or history thereof), or loss to follow-up (LTFU). Community outreach workers visited 
subjects at home if blood cultures were positive or if patients defaulted, unless subjects 
refused. Physician–investigators provided on-site supervision, including direct observation 
of clinician/patient encounters. We sought to enroll 324 subjects; our sample size estimates 
have been previously described.9
Statistical analyses were conducted in Stata 11.2 (Stata Corporation, College Station, TX). 
Etiologic diagnoses were limited to blood culture–confirmed bacteremia, smear-positive 
pulmonary TB, and malaria by rapid antigen test. Syndromic diagnoses were based on 
clinicians’ application of Mozambican guidelines. We defined diagnosis of “specific fever 
focus” as clinician identification of a likely fever source linked to a single organ system (eg, 
pneumonia, pelvic inflammatory disease, or varicella zoster). Syndromic diagnoses of 
“suspected bacteremia” or “suspected bacterial infection (not otherwise specified)” were not 
considered indicative of localized fever foci.
We described subjects’ baseline characteristics with proportions or medians with 
interquartile ranges. To describe associations between outcomes and subject characteristics, 
we used bivariate and multivariable logistic regressions. The composite adverse dependent 
outcome included death or hospitalization; patients with unknown outcomes were excluded.
The study protocol was approved by the Mozambican National Bioethics Committee and 
Vanderbilt University’s Institutional Review Board. Study coordinators obtained informed 
consent (written or witnessed oral consent) at enrollment.
RESULTS
Recruitment occurred from May–August 2012. Enrollment was truncated at 258 subjects 
because of administrative deadlines and limited incubator capacity. The subjects’ 
characteristics at enrollment are described in Table 1.
At enrollment, 13 subjects (5.0%) were hospitalized, and clinicians assigned 421 etiologic or 
syndromic diagnoses of fever. At least one localized fever focus was detected in 149 [57.8%, 
95% confidence interval (CI): 51.5 to 63.9] subjects; the most common were acute 
respiratory infection [95 (36.8%)], suspected TB [74 (28.7%)], and malaria [38 (14.7%)]. 
The most frequently assigned diagnosis was presumed bacteremia [138 (53.5%)], often 
given to subjects with signs or symptoms implicating multiple organ systems: 2 or more in 
135 (97.8%) and 3 or more in 106 (76.8%). Only 41 (15.9%) subjects acquired etiologic 
diagnoses (malaria or smear-positive pulmonary TB) at enrollment.
Of 245 subjects not hospitalized at enrollment, 46 (18.8%) received antimalarials and 220 
(89.8%) antibiotics. The 11 subjects not prescribed antibiotics or antimalarials were 
diagnosed with herpes zoster (3), suspected TB (1), uncomplicated upper respiratory 
infection (1), oral candida (1), and no diagnosis (5).
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Of 38 subjects with malaria antigenemia at enrollment, 32 (84.2%) had slide-confirmed 
parasitemia, 1 (2.6%) had negative microscopy, and 5 (13.2%) had no result because of 
reagent stockouts. Nine others with negative tests were prescribed antimalarials.
Of 258 sets of blood cultures drawn at enrollment, 39 (15.1%, 95% CI: 11.0 to 20.1) yielded 
pathogens (previously described).9 Briefly, 32 (82.9%) were nontyphoid Salmonella (NTS), 
largely resistant to multiple first-line antibiotics. Of 4 Streptococcus pneumoniae isolates, 2 
(50%) were resistant to penicillin and 1 (25%) to erythromycin. Most bacteremic subjects 
[26 (66.7%)] reported both gastrointestinal and respiratory symptoms. At enrollment, 5 
(12.8%) were hospitalized, 17 (43.6%) were prescribed antibiotics for presumed bacteremia, 
and 11 (28.2%) were prescribed antibiotics for other conditions. Of 31 subjects with drug-
resistant NTS or S. pneumoniae bacteremia, 10 required hospitalization (5 at enrollment and 
5 after failure of ineffective antibiotics prescribed at enrollment). Of the 21 remaining 
subjects, 18 were prescribed effective antibiotics (predominantly ciprofloxacin) at 
enrollment and 3 subsequently required switching to effective antibiotics.
At study visit 2, 220 (89.8%) of 245 patients not hospitalized at enrollment were 
reevaluated. Most [186 (84.9%)] had improved, but 11 (5.0%) were hospitalized, and 23 
(10.5%) were still symptomatic though ambulatory. Bacteremia and/or TB-related concerns 
were associated with most hospitalizations and failures to improve. One additional patient 
died (cause unknown) before the second visit.
After visit 2, 5 additional adverse outcomes occurred. Two deaths before study discharge 
were associated with treatment nonadherence and very late diagnosis of HIV/AIDS, 
respectively. Two deaths and 1 hospitalization occurred after improvement of fever: 1 death 
associated with progressively worsening anemia of unknown etiology after apparent 
recovery from Escherichia coli bacteremia, 1 death of unknown cause, and 1 hospitalization 
for recurrent fever with respiratory distress.
Before study initiation, the study clinicians had no experience with bacteremia. After the 
first 15 cases (80% NTS) were identified, antibiotic prescription increased from 56/76 
subjects (73.7%) to 167/182 (91.8%, P < 0.001) at enrollment and shifted from usual first-
line agents (eg, amoxicillin) to ciprofloxacin and azithromycin.
Ultimately, 196 (76.0%) subjects improved by visit 4 and 35 (13.6%) were hospitalized or 
died. The remaining 27 (10.5%) were LTFU. Only 82 (31.8%) ever acquired etiologic 
diagnoses, including 8 with confirmed malaria/NTS, TB/malaria, or TB/bacteremia 
coinfection.
For subjects not LTFU, lower or missing CD4, lower hemoglobin, lower body mass index, 
weight loss, esophageal candidiasis, syndromically diagnosed TB, and confirmed bacteremia 
were significantly associated with the composite adverse outcome by logistic regression 
(Table 2). Adjustment for interaction between bacteremia and antibiotic use attenuated the 
association between bacteremia and adverse outcomes [odds ratio (OR) = 0.71, 95% CI: 
0.11 to 4.48, if antibiotics were prescribed at the initial visit]. Even in the absence of 
bacteremia, antibiotics were protective (OR = 0.54, 95% CI: 0.30 to 1.00). The OR for 
association with adverse outcomes was highest for patients with CD4 <350 cells per 
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microliter who were not on antiretroviral therapy (ART) (OR = 11.86, 95% CI: 7.18 to 
19.59) as compared with patients with higher CD4 counts (reference category). The OR for 
association of smear-positive pulmonary TB and adverse outcomes was undefined because 
no subjects with smear-positive TB had adverse outcomes.
DISCUSSION
Nonphysician clinicians, using a largely syndromic Mozambican fever guideline, identified 
specific probable foci of fever in 149 (57.8%) HIV-infected adult subjects at enrollment, and 
the lower limit of the 95% CI (51.5%) exceeded the 50% threshold considered in our sample 
size9 calculations. Only 46 subjects (17.8%) were treated for malaria, 37 of whom (80.4%) 
had positive malaria tests, thus avoiding unnecessary malaria treatment in the majority and 
supporting Mozambique’s malaria testing policy.
Although fewer than 60% of subjects acquired diagnoses associated with specific fever foci 
at enrollment, nearly 90% of subjects not hospitalized were prescribed antibiotics. Antibiotic 
prescription may have been prompted by high symptom burdens, high prevalence of 
respiratory symptoms suggesting bacterial pneumonia, or by concern that failure to prescribe 
effective antibiotics might result in clinical deterioration of bacteremic subjects before 
receipt of blood culture results.
Encouragingly, 186 (84.6%) of 220 subjects seen in follow-up had improved by visit 2 and 
were discharged from the study, but it is unclear without counterfactual evidence whether the 
guideline’s recommendations actually caused the observed improvement in those without 
laboratory-confirmed malaria or TB.
Without blood cultures, antimicrobial susceptibility testing, and active tracing (all study, not 
routine, procedures), all 31 subjects with drug-resistant bacteremia would probably have 
been treated ineffectively with first-line antibiotics. Had all required hospitalization, 
observed adverse outcomes would have increased by more than 50%.
In subjects without confirmed bacteremia, antibiotics may still have been beneficial. The 
sensitivity of blood cultures may be less than 40%.10,11 If this estimate is generalizable to 
our subjects, the true number with bacteremia that responded to antibiotics may have been 
higher. Then again, if viral etiologies of acute respiratory infection were as common as has 
been reported elsewhere, overprescription of antibiotics may have been substantial.12,13 
Based on the available evidence, we are unable to determine which individual subjects had 
blood culture–negative bacterial infections responsive to presumptive antibiotics vs. 
spontaneous resolution of viral infections.
Both delayed evaluation of TB suspects and presumptive diagnosis of smear-negative TB 
were associated with initial management failure and/or adverse outcomes. This may reflect 
late diagnosis of genuine TB or persistent TB-like pulmonary symptoms actually caused by 
other opportunistic diseases that could not be diagnosed locally. Untreated AIDS was also 
significantly associated with poor outcomes.
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Because our sample was nonrandom, the 95% CIs around our point estimates must be 
interpreted cautiously. Our findings are likely generalizable to other Mozambican settings, 
though, because malaria and TB are present nationwide, late ART initiation is common, and 
drug-resistant NTS has been described in southern Mozambique and neighboring Malawi.
14–16
Although the majority of subjects improved, nearly 1 in 7 had adverse outcomes, etiologic 
diagnoses were confirmed in fewer than one-third, potentially fatal bacteremia diagnoses 
would have been missed in more than one-sixth without blood cultures (largely unavailable 
in Mozambique), and the combination of high symptom burdens and limited diagnostic 
capacity often precluded identification of a single fever cause. Overprescription of 
antibiotics may have succeeded overprescription of antimalarials as a management error, but 
the exact magnitude of overprescription is uncertain because the proportion of blood 
culture–negative patients who did have bacterial infections is unknown.
Our findings do not support the assumption that malaria testing, focused history, and 
physical examination will correctly identify a single unique fever focus in HIV-infected 
patients.
Possible strategies for improvement of guideline performance might include the following: 
enhanced microbiologic surveillance, improved access to rapid TB testing, evidence-based 
guidelines for presumptive antibiotic prescription, consistent restaging of febrile HIV-
infected patients, guidance for prioritization of interventions in patients with multiple signs/
symptoms, and revision of danger sign criteria. Clinical and operational research, aggressive 
scale-up of existing interventions, and more timely ART initiation will be required to further 
this life-saving agenda.
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TABLE 1
Characteristics of Fever Study Subjects at Enrollment (Study Visit 1), Overall and by Study Outcome
Patient Characteristic, n (%) or Median 
(Interquartile Range)
All Subjects (n = 
258)
Study End Points
Improved (n = 196)
Hospitalized or 
Died (n = 35) LTFU (n = 27)
Demographics
 Site
  Coalane     77 (29.8)     60 (30.6)       9 (25.0)       8 (29.6)
  Inhassunge     94 (36.4)     70 (35.7)     13 (37.1)     11 (40.7)
  Namacurra     87 (33.7)     66 (33.7)     13 (37.1)       8 (29.6)
 Gender, pregnancy status
  Pregnant     11 (4.3)       8 (4.1)       1 (2.9)       2 (7.4)
  Female, nonpregnant   163 (63.2)   127 (64.8)     19 (54.3)     17 (63.0)
  Male     84 (32.6)     61 (31.1)     15 (42.9)       8 (29.6)
 Age (yrs)     30 (25–38)     30 (25–38)     33 (27–40)     30 (25–36)
 Illiterate   113 (43.8)     80 (40.8)     19 (54.3)     14 (51.9)
 Did not permit home visits     13 (5.0)       7 (3.6)       1 (2.9)       5 (18.3)
HIV/AIDS status
 Current CD4 (cells/μL)* (65 missing)   225 (93–434) 254.5 (99–458.5)   134 (91–221)   194 (55–480)
 CD4 (cells/μL), categories
  <200     89 (34.5)     61 (31.1)     18 (51.4)     10 (37.0)
  200–349     37 (14.3)     30 (15.3)       6 (17.1)       1 (3.7)
  350–499     30 (11.6)     24 (12.2)       1 (2.9)       5 (18.5)
  ≥500     37 (14.3)     33 (16.8)       1 (2.9)       3 (11.1)
  None available     65 (25.2)     48 (24.5)       9 (25.7)       8 (29.6)
 Co-trimoxazole prophylaxis   170 (65.9)   136 (69.4)     19 (54.3)     15 (55.6)
 ART     91 (35.3)     75 (38.3)       9 (25.7)       7 (25.9)
 Eligible for ART but not on treatment   106 (41.1)     73 (37.2)     22 (62.9)     11 (40.7)
Vital signs
 Axillary temperature (°C)  37.6 (37.2–38.2)  37.6 (37.2–38.2)  37.7 (37.4–38.7)  37.5 (37.2–38.6)
 Body mass index (kg/m2) (6 missing)  19.5 (17.5–21.3)  19.8 (17.7–21.5)  18.0 (16.5–18.9)  19.1 (17.2–21.3)
Hemoglobin
 Hemoglobin (g/dL) (2 missing)  10.3 (8.8–12.0)  10.7 (9.0–12.5)     9.0 (7.4–10.5)     9.5 (8.5–10.8)
Comorbidities
 Peripheral neuropathy       2 (0.8)       2 (1.0)             0             0
 Sexually transmitted infection (excludes pelvic 
inflammatory disease)
    14 (5.4)     11 (5.6)       2 (5.7)       1 (3.7)
 Oral candidiasis     14 (5.4)       9 (4.6)       4 (11.4)       1 (3.7)
 Suspected esophageal candidiasis       7 (2.7)       3 (1.5)       3 (8.6)       1 (3.7)
 Cutaneous mycosis       6 (2.3)       5 (2.6)       1 (2.9)             0
 Suspected Kaposi sarcoma       5 (1.9)       5 (2.6)             0             0
 Active TB not yet diagnosed by clinician 
(discovered later in study)
    20 (7.8)     13 (6.6)       4 (11.4)       3 (11.1)
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Patient Characteristic, n (%) or Median 
(Interquartile Range)
All Subjects (n = 
258)
Study End Points
Improved (n = 196)
Hospitalized or 
Died (n = 35) LTFU (n = 27)
Symptoms
 Cough   178 (69.0)   136 (69.4)     25 (71.4)     17 (63.0)
 Any upper respiratory symptom (sore throat, 
sneezing, congestion, ear pain)
  181 (70.2)   135 (68.9)     23 (65.7)     23 (85.2)
 Any lower respiratory symptom (dyspnea, 
chest pain, hemoptysis)
  172 (66.7)   128 (65.3)     26 (74.3)     18 (66.7)
 Any gastrointestinal symptom (nausea, 
vomiting, diarrhea, abdominal pain)
  155 (60.1)   117 (59.7)     22 (62.9)     16 (59.3)
 Any genitourinary symptom (discharge, 
dysuria, ulcer)
    56 (21.7)     39 (19.9)     12 (34.3)       5 (18.5)
 Headache   214 (83.0)   164 (83.7)     27 (77.1)     23 (85.2)
 Skin problems (rash, lymphadenopathy)     18 (7.0)     14 (7.1)       3 (8.6)       1 (3.7)
 Weight loss     74 (28.7)     48 (24.5)     19 (54.3)       7 (25.9)
*
Results from testing ≤6 months before enrollment or after enrollment if no reported CD4 count result in the preceding 6 months.
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TABLE 2
Bivariate and Multivariable Correlations Between Subject Characteristics at First Study Visit and Study 
Outcome
Subject Characteristics at First Study Visit (n = 231 
Subjects Who Improved, Died, or Were 
Hospitalized; Subjects With Unknown Outcomes 
Were Excluded)
Bivariate Associations With Death or 
Hospitalization (n = 231)
Multivariable Associations With 
Death or Hospitalization, Adjusted 
for Presumed Correlation of 
Outcomes Within Sites (n = 224)
OR (95% CI) P OR (95% CI) P
Demographics
 Site
  Coalane Reference — — —
  Inhassunge 1.24 (0.49 to 3.10) 0.648 — —
  Namacurra 1.31 (0.52 to 3.29) 0.561 — —
 Gender, pregnancy status
  Pregnant 0.84 (0.10 to 7.06) 0.869 — —
  Female, nonpregnant Reference — — —
  Male 1.64 (0.78 to 3.45) 0.190 — —
 Age (yrs) 1.01 (0.97 to 1.05) 0.615 — —
 Illiterate 1.72 (0.84 to 3.55) 0.141 — —
 Did not permit home visits 0.79 (0.10 to 6.66) 0.141 — —
HIV/AIDS status
 CD4 (cells/μL), categories
  <350 7.52 (1.71 to 33.02) 0.008 No ART: 11.86 (7.18 to 
19.59)
<0.001
On ART: 4.51 (1.08 to 
18.84)
0.039
  ≥350 Reference — Reference —
  No CD4 result available 5.34 (1.10 to 25.93) 0.038 4.76 (1.63 to 13.93) 0.004
 ART* 0.56 (0.25 to 1.26) 0.159 See above —
 Eligible for ART but not on ART* 2.85 (1.35 to 6.00) 0.006 — —
 Co-trimoxazole prophylaxis† 0.53 (0.25 to 1.09) 0.083 0.43 (0.12 to 1.66) 0.232
Vital signs
 Axillary temperature (°C) 1.24 (0.84 to 1.84) 0.284 — —
 Body mass index (kg/m2) (6 missing) 0.80 (0.69 to 0.92) 0.002 0.92 (0.89 to 0.96) <0.001
Hemoglobin
 Hemoglobin (g/dL) (2 missing) 0.70 (0.58 to 0.84) <0.001 0.70 (0.58 to 0.85) <0.001
Comorbidities‡
 Sexually transmitted infection (excluding pelvic 
inflammatory disease)
1.02 (0.22 to 4.81) 0.981 — —
 Oral candidiasis 2.68 (0.78 to 9.24) 0.118 — —
 Esophageal candidiasis (presumed) 6.03 (1.17 to 31.20) 0.032 6.59 (1.12 to 38.85) 0.037
 Cutaneous mycosis 1.12 (0.13 to 9.92) 0.917 — —
Symptoms
 Cough 1.10 (0.50 to 2.44) 0.809 — —
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Subject Characteristics at First Study Visit (n = 231 
Subjects Who Improved, Died, or Were 
Hospitalized; Subjects With Unknown Outcomes 
Were Excluded)
Bivariate Associations With Death or 
Hospitalization (n = 231)
Multivariable Associations With 
Death or Hospitalization, Adjusted 
for Presumed Correlation of 
Outcomes Within Sites (n = 224)
OR (95% CI) P OR (95% CI) P
 Any upper respiratory symptom (sore throat, 
sneezing, congestion, ear pain)
0.87 (0.40 to 1.85) 0.711 — —
 Any lower respiratory symptom (dyspnea, chest 
pain, hemoptysis)
1.53 (0.68 to 3.46) 0.302 — —
 Any gastrointestinal symptom (nausea, vomiting, 
diarrhea, abdominal pain)
1.14 (0.54 to 2.40) 0.725 — —
 Any genitourinary symptom (discharge, dysuria, 
ulcer)
2.10 (0.96 to 4.59) 0.063 — —
 Headache 0.66 (0.27 to 1.58) 0.350 — —
 Skin problems 1.21 (0.30 to 4.48) 0.766 — —
 Weight loss 3.66 (1.75 to 7.68) 0.001 5.69 (2.22 to 14.56) <0.001
Diagnoses/treatment at visit 1
 Malaria antigenemia 0.89 (0.32 to 2.46) 0.818 — —
 Slide-confirmed malaria parasitemia 0.79 (0.26 to 2.43) 0.685 — —
 Smear-positive TB (new diagnosis)‡ Undefined — — —
 Smear-negative TB (new diagnosis) 3.58 (0.82 to 15.72) 0.091 14.45 (1.43 to 146.42) 0.024
 TB suspect§ 2.91 (1.39 to 6.09) 0.005 — —
 Blood culture drawn at this visit detects 
bacteremia║
2.87 (1.26 to 6.52) 0.012 Bacteremia, no 
antibiotics: 12.51 (2.21 
to 70.86)
0.004
— — Bacteremia, antibiotics: 
0.71 (0.11 to 4.48)
0.719
 Antibiotics prescribed║ 0.18 (0.08 to 0.42) <0.001 Antibiotics, no 
bacteremia: 0.54 (0.30 
to 1.00)
0.048
— — No antibiotics, no 
bacteremia: reference
—
 Antimalarials prescribed 0.72 (0.26 to 1.97) 0.518 — —
 Start TB treatment 5.73 (0.35 to 93.9) 0.221 — —
 Start antiretrovirals 0.41 (0.05 to 3.27) 0.403 — —
*
In multivariable model, ORs for association of CD4 category and outcomes are adjusted for interactions of CD4 <350 cells per microliter and 
ART.
†
Retained in model because of a priori assumption that co-trimoxazole prophylaxis would be negatively associated with febrile illnesses.
‡New diagnosis for smear-positive TB dropped owing to zero cell sizes (no cases of hospitalization or death).
§
Dropped from multivariable model because of collinearity.
║
In multivariable model, adjusted for interaction between blood culture results and antibiotic prescription at visit 1.
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